Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


21.01.2019

1 Ann Neurol
1 Eur Neurol
1 J Neurol
3 J Neurol Neurosurg Psychiatry
3 JAMA
1 Mult Scler
3 Neurology
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Neurol

  1. BAERT L, Benkhoucha M, Popa N, Ahmed MC, et al
    APRIL-mediated anti-inflammatory response of astrocytes in multiple sclerosis.
    Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25415.
    PubMed     Text format     Abstract available


    Eur Neurol

  2. LADEIRA F, Salavisa M, Caetano A, Barbosa R, et al
    The Influence of Menopause in Multiple Sclerosis Course: A Longitudinal Cohort Study.
    Eur Neurol. 2019;80.
    PubMed     Text format     Abstract available


    J Neurol

  3. LAVORGNA L, Esposito S, Lanzillo R, Sparaco M, et al
    Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.
    J Neurol. 2019 Jan 16. pii: 10.1007/s00415-019-09193.
    PubMed     Text format     Abstract available


    J Neurol Neurosurg Psychiatry

  4. KALINCIK T, Kubala Havrdova E, Horakova D, Izquierdo G, et al
    Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 13. pii: jnnp-2018-319831.
    PubMed     Text format     Abstract available

  5. FAREZ MF
    Food allergies and multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 10. pii: jnnp-2018-319585.
    PubMed     Text format    

  6. ATKINS HL
    Another brick in the wall: further evidence supporting the role of haematopoietic stem cell transplantation in treating multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 10. pii: jnnp-2018-319715.
    PubMed     Text format    


    JAMA

  7. ATKINS H
    Stem Cell Transplantation to Treat Multiple Sclerosis.
    JAMA. 2019;321:153-155.
    PubMed     Text format    

  8. BROWN JWL, Coles A, Horakova D, Havrdova E, et al
    Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    JAMA. 2019;321:175-187.
    PubMed     Text format     Abstract available

  9. BURT RK, Balabanov R, Burman J, Sharrack B, et al
    Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
    JAMA. 2019;321:165-174.
    PubMed     Text format     Abstract available


    Mult Scler

  10. MARRODAN M, Alessandro L, Farez MF, Correale J, et al
    The role of infections in multiple sclerosis.
    Mult Scler. 2019 Jan 14:1352458518823940. doi: 10.1177/1352458518823940.
    PubMed     Text format     Abstract available


    Neurology

  11. ZETTERBERG H, Svenningsson A
    Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006906.
    PubMed     Text format    

  12. HONCE JM, Nair KV, Sillau S, Valdez B, et al
    Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006916.
    PubMed     Text format     Abstract available

  13. COHEN BA
    Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006924.
    PubMed     Text format    


    PLoS One

  14. DUQUETTE P, Yeung M, Mouallif S, Nakhaipour HR, et al
    A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
    PLoS One. 2019;14:e0210417.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: